Introduction Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury. However, the clinical efficacy of the medication has not been convincingly demonstrated. Methods We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome. Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies. Authors were contacted if necessary. ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE. The primary outcome was mortality within 28-30 days after randomization. Relative risks were pooled with the random effect model. Results 8 trials were included in the analysis. There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26). Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28). There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO2/FiO2 ratio (0.30, 0.05 to 0.56). Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias. Conclusion Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.
Objective
Ideal management of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remains controversial. Current evidence suggests that low tidal volume mechanical ventilation is associated with decreased mortality (1), but even with decreased tidal volume, the mortality of ALI/ ARDS remains high (2) . Many pharmacologic treatments have been studied, such as corticosteroids, alprostadil, acetylcysteine, surfactant, or pentoxifylline (3, 4) , but data on these medications are limited and their effectiveness remains controversial.
Sivelestat, a neutrophil elastase inhibitor, was developed in Japan (5) . Neutrophil elastase is a protease produced by inflammatory cells and its inhibition is associated with prevention of acute lung injury in animal models (6) . After a phase 3 trial (7), sivelestat was approved in Japan for the treatment of ALI with systemic inflammatory response syndrome (SIRS), and it is widely used in this country. However, its efficacy has not been well documented. To evaluate the efficacy of sivelestat on ALI/ARDS, we conducted a systematic review and meta-analysis on clinical outcomes, such as mortality.
Methods
We searched MEDLINE (source, PubMed, 1966 to February 2010), EMBASE (1974 to February 2010 , ICHUSHI (1983 to February 2010 , and Cochrane Database of Systematic Reviews (through March 2010). ICHUSHI is an abbreviation for Igaku-Chuo Zasshi (Japanese Central Revue of Medicine), the Japanese database for medical journals, produced by the Japan Medical Abstract Society, the largest database for medical articles in Japan, and entails more than 5,000 journals, with many published articles and abstracts of scientific meetings, mainly written in Japanese. We also searched the reference lists of included studies. Non-English language articles such as Japanese articles were included in this analysis.
Each search query included terms, sivelestat, Elaspol (for its brand name), and eraspol (for potential misspelling), and for ICHUSHI these terms in Japanese characters were also used for search. Only prospective randomized controlled trials (RCTs) were considered for inclusion in this metaanalysis. Alternating allocation of the patients (quasirandomization) was accepted to include in the analysis. Only studies on treatment of patients with ALI and/or ARDS were included in the analysis. Studies of sivelestat on prophylactic use were excluded. We used authors' definitions of acute lung injury and acute respiratory distress syndrome.
Two reviewers (K. I. and A. D.) independently and in duplicate scanned all titles and abstracts that indicated the study was RCTs evaluating the use of sivelestat to humans. Two reviewers independently extracted data from full text papers. Differences in the data extracted were resolved by discussion with a third reviewer (H.O.). For each study, we extracted data on baseline characteristics (age, sex, initial PaO2/FiO2 ratio, Acute Physiology and Chronic Health Evaluation (APACHE) II score, reason for developing ALI/ ARDS if available) of study population. We contacted authors and requested additional data for inclusion in the meta-analysis if needed. If multiple publications by the same investigators existed, these studies were reviewed to make sure data were not analyzed in duplicate. If not clear, the authors were also contacted for confirmation.
We used CONSORT (Consolidated Standards of Reporting Trials) 2010 statement and its check list for quality assessment (8) (9) (10) .
The primary outcome was all-cause mortality at 28 or 30 days after randomization (28-30 days mortality). The secondary outcomes were mortality at 180 days after randomization (180 days mortality), duration of mechanical ventilation, and PaO2/FiO2 ratio on day 3 (48 hours after randomization). For the primary outcome, we planned subgroup analysis a priori based on the countries where the studies were conducted (Japan vs others), since the potential heterogeneity on the efficacy of sivelestat between Japanese population and non-Japanese was discussed (11) . Also, other subgroup analyses on the primary outcome were planned if meta-analysis showed heterogeneity among studies.
All statistical tests were 2-sided, and we considered p< 0.05 to be statistically significant. We reported continuous outcomes as weighted mean differences (a measure of absolute change) for number of days of mechanical ventilation and PaO2/FiO2 ratio (12) . We report binary outcomes (mortality) as risk ratios (RRs). All outcomes are presented with 95% confidence intervals (CIs). Two reviewers (K.I. and T. S.) independently conducted each analysis to minimize data management errors (13) .
We measured heterogeneity and expressed it as I 2 , the percentage of total variation across studies owing to betweenstudy heterogeneity rather than chance (14, 15) , with suggested thresholds for low (I 2 =25%-49%), moderate (I 2 = 50%-74%) and high (I 2 !75%) values (15) . Meta-analyses were done with random-effects model, to provide more conservative treatment estimates when heterogeneity is present (16) . To assess publication bias, we visually examined the funnel plot for mortality and performed Egger's regression test (17) . Analyses were performed using STATA version 10.1 for Macintosh (StataCorp, College Station, TX).
Results

Literature search
Detailed search steps are summarized in a flowchart illustrating the mechanisms of exclusion for certain studies ( Fig. 1 ) in accordance with the Quality of Reporting of Meta-analyses (QUOROM) recommendations (18) . We initially identified 1499 potentially relevant articles and abstracts. All articles and abstracts were written either in English or Japanese and we did not have to use a translation service. Thirty-eight articles were considered to be of interest and were retrieved for detailed evaluation. Thirty articles that did not meet our criteria were excluded, and the remaining 8 articles were included in the meta-analysis. Study characteristics and methodological quality are shown on Table 1. The authors of three trials (number 1, 6, 8) were contacted for further information. The quality of these trials was assessed using CONSORT 2010 statement, and the fulfillment of recommendation was summarized in Table 2a and 2b.
There were many methodological problems in the studies we included. Many items on CONSORT 2010 checklist were not stated. Only 4 out of 8 studies described methods used to generate the random allocation sequence (Item 8a) and one out of 4 studies used quasi-randomization (alternate assignment) for patient allocation. Only 1 out of 8 studies had adequate allocation concealment described, and only 3 Records identified and screened. n=1499
1461 excluded based on title and /or abstract due to animal studies, non-comparative studies, retrospective case control studies, reviews, correspondence, editorials, or studies on markers not relevant to clinical outcomes (such as biomarkers).
Records retrieved for more detailed evaluation. n = 38
Trials included in review. n = 8
Excluded n = 30 Data on prophylactic use n=8 Not prospective n= 8 Determined to be nonrandomized n = 5 Unable to determine if randomized n=1 Duplicates of the same data n = 6 Study on different disease n=1 Data on outcomes not provided n=1 out of 8 studies used blinding (Item 11a, and 11b). Only 2 out of 8 studies described primary and secondary outcomes, with the estimated effect size and its precision (Item 17a and 17b). Only one study discussed the limitation of the study (Item 20). One trial ended early (Study 3). 
Clinical Outcomes
Mortality
Only 5 studies provided data on 28-30 days mortality. Only 2 studies provided data on 180 days mortality. In the analysis on primary outcome, sivelestat had no effect on short term (28-30 days) mortality (Risk Ratio 0.95 Confidence Interval 0.72-1.26) (Fig. 2) . For 180 days mortality, sivelestat was associated with a worse outcome (RR 1.27, CI 1.00-1.62) (Fig. 3) . Predetermined sub-group analysis on studies conducted in Japan only, by excluding one study by Zeiher et al (21) , again demonstrated no benefit of sivelestat on short term mortality (RR 0.59, CI 0.28-1.28) (Fig. 4) . Only one study conducted in Japan provided data on 180 (2008)]. All mortality analyses showed little to no statistical heterogeneity beyond that expected by chance (I 2 <10%). For primary outcome, we found no significant funnel plot asymmetry both on visual inspection (Fig. 7) and by Egger's test (p=0.206), suggesting no underpublication of negative results.
Other respiratory profiles
For respiratory profile, only ventilator days and PaO2/FiO2 ratio on day 3 (48 hours after randomization) were used as continuous variables, since few other parameters were given in details for the meta-analysis in studies included. For ventilator days, 3 studies provided data for meta-analysis, and there was no statistical difference (standardized mean difference -0.43, CI -1.12 to 0.27) (Fig. 5) . There was moderate heterogeneity among these studies (I 2 =73.7%). For PaO2/ FiO2 ratio on day 3, only 2 studies provided data for metaanalysis, and sivelestat was associated with better PaO2/FiO2 ratio comparing with control (SMD 0.30, CI 0.05 to 0.56) (Fig. 6 ). There was little to no statistical heterogeneity beyond that expected by chance (I 2 =0.0%). 
Discussion
Our systematic review and meta-analysis suggests that sivelestat does not decrease mortality for patients with acute lung injury and acute respiratory distress syndrome. It was true even when only RCTs conducted in Japan were included in the analysis. Even though sivelestat may be associated with improvement of oxygenation for a short period, the analysis did not show the shortening of ventilator days by use of sivelestat. Therefore, the effect of sivelestat on patients with ALI/ARDS appears to be modest, if any.
Our analysis suggested that there was little heterogeneity among studies included in this analysis. In addition, our funnel plot did not suggest publication bias. In general, publication bias tends to occur with the result tendency tilting towards the benefit of the medication investigated. It is unlikely that there are studies not published, which demonstrated the positive effects of sivelestat to rebut our results.
Sivelestat was developed in Japan and has been widely used for the treatment of ALI/ARDS. However, a subsequent multinational randomized double-blinded trial did not demonstrate the improvement in both short-term (28 days) and long-term (180 days) mortality (21) . As a result, most countries have not approved sivelestat and it is not used for the treatment of ALI/ARDS.
On the other hand, sivelestat continues to be used in Japan. Many small studies conducted in Japan suggested that sivelestat might be associated with improvement in respiratory profiles, particularly when it was used early. Many case reports with successful outcomes supported its use too. Also, there is controversy as to whether results of studies conducted outside Japan are applicable to Japanese people. We analyzed data including Japanese studies and the results were consistent with the RCT conducted abroad. In addition, we conducted subgroup analysis on studies conducted in Japan only, and sivelestat in this population was again not associated with improved mortality outcome. These results suggest the results of studies conducted outside Japan are applicable to Japanese people.
Many studies conducted in Japan are published in Japanese and many are not included in major database such as MEDLINE. Meta-analysis utilizing only these major databases may lead to exclusion of articles written in Japanese. Therefore, we included ICHUSHI, Japan's largest database for medical journals and abstracts. Indeed, among 1499 articles we found, 1207 were found in the analysis by ICHUSHI. MEDLINE, on the other hand, found only 229 articles. Only 48 articles were found on both databases. Among 8 articles we chose for the meta-analyses, 4 are written in Japanese and none of them are found on MED-LINE, EMBASE, or Cochrane Database of Systematic Reviews. It was pointed out that RCTs found in ICHUSHI may have good quality by CONSORT checklist but might be ignored by English-speaking investigators (27) . In our analyses, extensive literature search was done for both English and Japanese articles. Funnel plot with Egger's test also did not suggest publication bias. We consider potential publication bias due to the language of the article in our analysis very unlikely. There are several limitations in our analyses. First, the overall quality of RCTs included in the analyses was not good. Many studies did not blind patients, physicians and researchers. Most studies did not select mortality as outcome. Sample size of studies included in our analysis was generally small, and it made the weight of one study stand out from the others. However, excluding this study did not alter the primary outcome. Second, even though there was little or no statistical heterogeneity among studies for mortality outcome, with no significant difference in relative risks, there might be inter-study difference in terms of patient populations. Other treatment methods such as mode of ventilation, use of other medications, or the way fluid was administered might alter the outcome. The difference in the cause of ALI/ARDS might also affect the efficacy of sivelestat. To overcome these limitations, large RCTs need to be conducted while matching these parameters. Third, we excluded studies on the prophylactic use of sivelestat. In addi- tion, there is discussion regarding the use of sivelestat in the early phase of ALI/ARDS. To our knowledge, no study clearly demonstrated this benefit of sivelestat. Further studies are needed to clarify the efficacy of the medication on prophylaxis or early use.
In conclusion, sivelestat did not improve mortality outcome in the treatment of acute lung injury and acute respiratory distress syndrome in our meta-analysis. It was associated with better oxygenation on day 3 but did not alter the length of mechanical ventilation.
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